Communiqués Defence Therapeutics Inc.

Actions

DTC

CA24463V1013

Recherche biotechnologique et médicale

Marché Fermé - Canadian Securities Exchange 16:59:21 24/09/2026			Varia. 5j.	Varia. 1 janv.
0,4700 ^CAD	0,00 %		-4,08 %	-34,72 %

31/08	Defence Therapeutics élargit sa stratégie de développement radiopharmaceutique avec des programmes d'émetteurs alpha et bêta	CI
17/08	Defence Therapeutics Inc. annonce des changements au sein de sa direction	CI

Communiqués

08/09	Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders	NE
05/09	Defence Therapeutics Provides Updates on Sharing Agreement	NE
31/08	Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs	NE
17/08	Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs	NE
04/08	Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer	NE
08/07	Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform	NE
06/07	Defence Therapeutics : Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	PU
17/06	Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions	NE
03/06	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors	NE
01/06	Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors	NE
29/05	Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian	NE
19/05	Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities	NE
25/04	Defence Therapeutics Announces Grant of Restricted Stock Units	NE
20/03	Defence Therapeutics Announces Warrant Terms Amendment	NE
09/03	Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000	NE
02/03	Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March	NE
27/02	Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million	NE
10/02	Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board	NE
04/02	Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform	NE
28/01	Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline	NE
21/01	Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics	NE
11/12	Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
10/12	Defence Therapeutics Announces AGM Results and Provides Corporate Updates	NE
04/12	Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs	NE
24/11	Defence Therapeutics Announces Convertible Debenture Conversion	AQ